IN8bio (INAB)

• Market cap: $8.85M
• 1 day: -2.01%
• 5 days: -8.02%
• 1 month: -10.14%
• 3 months: -8.45%
• 6 months: -61.54%
• Year to date: -76.81%
• 1 year: -76.81%
• 5 years: -99.35%
• 10 years: -99.35%
• Sector: Healthcare
• Industry: Biotechnology

About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Employees: 18